Epidemiology and Risk Factors of Pancreatic Cancer

Molinari, Michele; Líu, Hao; Kaltenmeier, Christof

doi:10.5772/intechopen.109778

Cited by 3 publications

(1 citation statement)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pancreatic cancer is a multifactorial disease etiologically, with pathogenesis including several genetic and environmental factors such as cystic fibrosis, hereditary breast and ovarian cancer syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, hereditary pancreatitis, alcohol consumption, cigarette smoking, diabetes mellitus, obesity, and chronic pancreatitis [8].…”

Section: Introductionmentioning

confidence: 99%

On the Menu: Analyzing the Macronutrients, Micronutrients, Beverages, Dietary Patterns, and Pancreatic Cancer Risk

Mukhtar,

Moradi,

Kodali

et al. 2023

Cureus

View full text Add to dashboard Cite

This narrative review summarizes the principal findings of observational studies, systematic reviews, and meta-analyses on diet and dietary patterns' role in the risk of pancreatic cancer. Etiologically pancreatic cancer is multifactorial. Evidence exists of an association between nutrients, dietary patterns, and pancreatic cancer. An extensive literature search was conducted on PubMed, Cochrane, and Google Scholar. A thorough search of articles published in English till May 2023 and related to the review was performed. The relationship between all macronutrients, micronutrients, and various dietary patterns with the risk of pancreatic cancer was assessed. It is concluded that a diet high in nutrients like red and processed meat, refined sugars, saturated and monounsaturated fats, alcohol, copper, and a Western dietary pattern can increase the likelihood of pancreatic cancer. Contrary to this, a diet consisting of fruits, vegetables, appropriate quantities of vitamins and minerals, and a Mediterranean dietary pattern is associated with a decreased risk of pancreatic cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

On the Menu: Analyzing the Macronutrients, Micronutrients, Beverages, Dietary Patterns, and Pancreatic Cancer Risk

Mukhtar,

Moradi,

Kodali

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

Management of Pain and Cachexia in Pancreatic Cancer: Protocol for Two Systematic Reviews, Network Meta-Analysis, Surveys, and Focus Groups

Roberts¹,

Watson²,

Macdonald³

et al. 2023

JMIR Res Protoc

View full text Add to dashboard Cite

Background Approximately 75% of people with pancreatic cancer experience pain, and >50% of them have cachexia (weakness and wasting of the body). However, there is considerable uncertainty regarding the management of these distressing symptoms. Objective Our primary objectives are to compare the relative benefits and harms of different interventions for pain in people with unresectable pancreatic cancer and for prevention and treatment of cachexia due to pancreatic cancer, through systematic reviews and network meta-analysis. Our secondary objectives are to develop an evidence-based clinical care pathway to manage pain and prevent and treat cachexia in people with pancreatic cancer through surveys and focus groups involving patients, carers, and health care professionals. Methods We will perform 2 systematic reviews of the literature related to pain and cachexia in people with pancreatic cancer using searches from Cochrane Library, MEDLINE, Embase, Science Citation Index, and trial registries. Two researchers will independently screen for eligibility and identify randomized controlled trials (no language or publication status restriction), comparing interventions for pain or cachexia based on full-texts for articles shortlisted during screening. We will assess risk of bias in the trials using the Cochrane risk of bias tool (version 2.0) and obtain data related to baseline prognostic characteristics, potential effect modifiers and outcome data related to overall survival, health-related quality of life, treatment-related complications, and resource utilisation. We aim to conduct network meta-analysis on outcomes with multiple treatment comparisons where possible, otherwise, meta-analysis with direct comparisons, or narrative synthesis. We will perform various subgroup and sensitivity analyses. Using information obtained from both systematic reviews, we will conduct 2 surveys: one directed to patients or carers to assess acceptability of interventions, and the other to health care professionals to assess feasibility of delivery in the National Health Service. Four mixed focus groups will be conducted to evaluate findings and foster consensus in the development of the care pathway. Results Funding was awarded from April 2022 (NIHR202727). Both systematic review protocols were prospectively registered on PROSPERO in May 2022. Formal searches began thereafter. Approval by the University College London Research Ethics Committee (23563/001) was received in December 2022. Data collection began in January 2023; data analysis will begin in May 2023 (completion expected by October 2023). Conclusions This study will comprehensively encompass major interventions for management of pain in people with unresectable pancreatic cancer, and prevention and treatment of cachexia in people with pancreatic cancer. Key stakeholders will facilitate the development of an evidence-based care pathway, ensuring both acceptability and feasibility. The project ends in April 2024 and published results are expected within 12 months of completion. We aim to present the findings through patient group websites, conferences, and publications, irrespective of the findings, in a peer-reviewed journal. International Registered Report Identifier (IRRID) DERR1-10.2196/46335

show abstract

Management of Pain and Cachexia in Pancreatic Cancer: Protocol for Two Systematic Reviews, Network Meta-Analysis, Surveys, and Focus Groups (Preprint)

Roberts¹,

Watson²,

Macdonald³

et al. 2023

Preprint

View full text Add to dashboard Cite

UNSTRUCTURED Introduction: Approximately 75% of people with pancreatic cancer suffer with pain and more than half of patients have cachexia (weakness and wasting of the body). However, there is considerable uncertainty regarding the management of these distressing symptoms. Primary objectives: To compare the relative benefits and harms of different interventions for pain in people with unresectable pancreatic cancer and for the prevention and treatment of cachexia due to pancreatic cancer, through systematic reviews and network meta-analysis. Secondary objectives: To develop an evidence-based clinical care pathway for management of pain and for prevention and treatment of cachexia in people with pancreatic cancer through surveys and focus group discussions involving patients, carers and healthcare professionals. Methods and analysis: We will perform two systematic reviews of the literature related to pain and cachexia in people with pancreatic cancer using searches from Cochrane Library, MEDLINE, EMBASE, Science Citation Index and trial registries. Two researchers will independently screen against the eligibility criteria and identify randomised controlled trials (no language restriction) comparing interventions for pain or cachexia for inclusion based on full-texts for articles shortlisted during screening. We will assess risk of bias in the trials and obtain data related to baseline prognostic characteristics, potential effect modifiers, details of interventions, and outcome data related to overall survival, health-related quality of life, treatment-related complications and resource utilisation. We aim to conduct network meta-analysis on outcomes with multiple treatment comparisons where possible. Alternatively, we will perform standard meta-analysis with direct comparisons, or a narrative synthesis. We will perform various subgroup analyses, meta-regression and sensitivity analyses. Using information obtained from the two systematic reviews, we will conduct surveys and focus groups to assess the acceptability and feasibility of delivering interventions in the NHS. Ethics and dissemination: This project was approved by the UCL Research Ethics Committee (Ethics number: 23563/001). We aim to present the findings through patient group websites, conferences and publish the review, irrespective of the findings, in a peer-reviewed journal. PROSPERO registration numbers: CRD42022333239 and CRD42022333241

show abstract

Epidemiology and Risk Factors of Pancreatic Cancer

Cited by 3 publications

References 65 publications

On the Menu: Analyzing the Macronutrients, Micronutrients, Beverages, Dietary Patterns, and Pancreatic Cancer Risk

On the Menu: Analyzing the Macronutrients, Micronutrients, Beverages, Dietary Patterns, and Pancreatic Cancer Risk

Management of Pain and Cachexia in Pancreatic Cancer: Protocol for Two Systematic Reviews, Network Meta-Analysis, Surveys, and Focus Groups

Management of Pain and Cachexia in Pancreatic Cancer: Protocol for Two Systematic Reviews, Network Meta-Analysis, Surveys, and Focus Groups (Preprint)

Contact Info

Product

Resources

About